Want to see XNCR full AI Analyst Report?
XNCR Stock Chart & Stats
$19.44
$0.42(2.16%)
At close: 4:00 PM EDT
$19.44
$0.42(2.16%)
Day’s Range― - ―
52-Week Range$7.13 - $27.59
Previous Close$19.86
Volume942.30K
Average Volume (3M)1.04M
Market Cap
$1.89B
Enterprise Value$934.98
Total Cash (Recent Filing)$456.45M
Total Debt (Recent Filing)$65.21M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Nov 09, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding74,353,390
10 Day Avg. Volume1,146,628
30 Day Avg. Volume1,035,385
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.79
Price to Sales (P/S)9.05
P/FCF Ratio-8.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.29Price Target Upside55.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.03
Revenue Forecast (FY)$143.94M
Bulls Say, Bears Say
Bulls Say
Balance Sheet FlexibilityModerate-to-low leverage and a meaningful equity cushion provide financial flexibility as Xencor funds clinical development. This capital base can help absorb ongoing losses and support programs without the balance-sheet pressure associated with heavier debt.
Settlement Extends RunwayThe $105 million settlement materially improves funding visibility and extends the period available to advance the pipeline. Longer runway reduces near-term financing dependence and gives development programs more time to generate milestones or partnerships.
Antibody Engineering PlatformA differentiated antibody-engineering platform gives Xencor multiple opportunities to create biologic candidates across immuno-oncology and autoimmune markets. Its collaboration and licensing model can monetize the technology through upfronts, milestones, and royalties.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows that Xencor is not yet self-funding. Continued investment in clinical programs may require additional partnerships, licensing proceeds, or capital, creating ongoing funding risk despite the extended runway.
Weak ProfitabilityCosts remain well ahead of revenue, and negative operating results indicate limited current earnings power. Without successful clinical advancement, partnering, or commercialization, the company may remain dependent on irregular milestone revenue rather than recurring operating income.
Loss Of U.S. RoyaltiesAlthough the upfront payment improves liquidity, surrendering future U.S. Ultomiris royalties removes a potentially recurring revenue stream. Xencor therefore becomes more reliant on ex-U.S. royalties and the uncertain timing of other milestones and licenses.
Xencor News
XNCR FAQ
What was Xencor Inc.’s price range in the past 12 months?
Xencor Inc. lowest stock price was $7.13 and its highest was $27.59 in the past 12 months.
What is Xencor Inc.’s market cap?
Xencor Inc.’s market cap is $1.89B.
When is Xencor Inc.’s upcoming earnings report date?
Xencor Inc.’s upcoming earnings report date is Nov 09, 2026 which is in 80 days.
How were Xencor Inc.’s earnings last quarter?
Xencor Inc. released its earnings results on Aug 05, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.801 by $0.511.
Is Xencor Inc. overvalued?
According to Wall Street analysts Xencor Inc.’s price is currently Undervalued.
Does Xencor Inc. pay dividends?
Xencor Inc. does not currently pay dividends.
What is Xencor Inc.’s EPS estimate?
Xencor Inc.’s EPS estimate is -0.32.
How many shares outstanding does Xencor Inc. have?
Xencor Inc. has 74,353,390 shares outstanding.
What happened to Xencor Inc.’s price movement after its last earnings report?
Xencor Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.801. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Xencor Inc.?
Currently, no hedge funds are holding shares in XNCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.29 (55.79% Upside)
$30.29 (55.79% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.56%
Trailing 12-Months
Company Description
Xencor Inc.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XNCR Stock 12 Month Forecast
Average Price Target
$30.29
▲(55.79% Upside)
Technical Analysis
CytomX Therapeutics
―
AnaptysBio
―
Zymeworks
―
AbCellera Biologics
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.54% Insiders
29.30% Mutual Funds
3.88% Other Institutional Investors
40.14% Public Companies and
Individual Investors